<!DOCTYPE html>

<!--
  Created : 1/26/2012 1:57 PM
  Author : Tom Coleman
  Copyright : 2011-2011
  By : University of Missippi Medical Center
-->

<html>
<head>
<title> Model </title>
<link rel='stylesheet' type='text/css' href='../../Style.CSS'>
</head>

<body>

<img src='../../SmallTitle.PNG'>
<img src='../XMLLightBlue.png'>
<a href='Docs_Catechols.html'><img src='../../Back.PNG'></a>
<p>
QHP 2008 / Catechols.DOCS<br>
<br>
Created : 27-Mar-09<br>
Last Modified : 27-Mar-09<br>
Author : Tom Coleman<br>
Copyright : 2009<br>
<br>
&lt;structurename&gt; AlphaPool &lt;/structurename&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.Effect &lt;/name&gt;<br>
&lt;topic&gt; AlphaPool - Definition &lt;/topic&gt;<br>
&lt;topic&gt; Receptor Dynamics Overview1 &lt;/topic&gt;<br>
&lt;topic&gt; Adrenergic Receptors Overview1 &lt;/topic&gt;<br>
&lt;seealso&gt; MidodrinePool.[Midodrine] &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.EpiPart &lt;/name&gt;<br>
&lt;topic&gt; EpiPart - Definition1 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.EPISCALE &lt;/name&gt;<br>
&lt;topic&gt; EPISCALE - Definition1 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.MidoPart&lt;/name&gt;<br>
&lt;topic&gt; MidoPart - Definition1 &lt;/topic&gt;<br>
&lt;seealso&gt; MidodrinePool.[Midodrine] &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.MIDOSCALE &lt;/name&gt;<br>
&lt;topic&gt; MIDOSCALE - Definition1 &lt;/topic&gt;<br>
&lt;seealso&gt; MidodrinePool.[Midodrine] &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.NEPart&lt;/name&gt;<br>
&lt;topic&gt; NEPart - Definition1 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.NESCALE &lt;/name&gt;<br>
&lt;topic&gt; NESCALE - Definition1 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; AlphaPool.Total&lt;/name&gt;<br>
&lt;topic&gt; Total - Definition1 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; AlphaPool - Definition &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
The alpha pool is the quantity of stimulated alpha receptors.<br>
Under resting conditions the effect of alpha pool stimulation<br>
is 1.0 and norepinephrine and epinephrine make roughly equal<br>
contributions to the alpha pool. <br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Adrenergic Receptors Overview1 &lt;/name&gt;<br>
&lt;label&gt; Adrenergic Receptors Overview &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
There are two major types of adrenergic receptors, alpha <br>
receptors and beta receptors. Alpha receptors can be subdivided <br>
into alpha 1  and alpha 2 receptors. Beta receptors can be <br>
subdivided into beta 1 receptors and beta 2 receptors. <br>
Norepinephrine and epinephrine have slightly different effects <br>
in exciting the alpha and beta receptors. Norepinephrine excites <br>
mainly alpha receptors but excites beta receptors to a lesser <br>
extent as well. Epinephrine excites both types of receptors <br>
approximately equally. Therefore the relative effects of <br>
norepinephrine and epinephrine on different effector<br>
organs are determined by the types of receptors in the organs.<br>
Furthermore certain alpha functions are excitatory, whereas <br>
others are inhibitory. Likewise certain beta functions are <br>
excitatory and others are inhibitory. Therefore, alpha and beta <br>
receptors are not necessarly associated with excitation or <br>
inhibition but simply with the affinity of the hormone for the <br>
receptors in the given effector organ.  <br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Receptor Dynamics Overview1  &lt;/name&gt;<br>
&lt;label&gt; Receptor Dynamics Overview &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Besse J, Furchgott R. Dissociation constants and relative <br>
efficacies of agonists acting on adrenergic alpha-receptors. <br>
Fed Proc 26: 410, 1967<br>
<br>
Clark JW, Leff P. Operational models of pharmacological<br>
agonism. Proc R. Soc Lond 220: 141-162, 1983.<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; NESCALE - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt; <br>
<br>
NESCALE is a constant which relates plasma levels of <br>
norepinephrine to alpha agonism. Together with EPISCALE,<br>
normal plasma levels of epinephrine and NE are mapped to<br>
an alpha agonism of 1.0. <br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; NEPart - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Since alpha receptors see both epinephrine and norepinephrine, <br>
the blood concentration of Epi and NE do not quantitate their<br>
effect on alpha receptors. In the model NE and Epi contribute <br>
equally to alpha agonism and normal plasma concentrations of <br>
NE and Epi are mapped to an alpha agonism of 1.0. This is done <br>
by using two constants NESCALE and EPISCALE to calculate NEPart <br>
and EpiPart respectively. <br>
<br>
Besse J, Furchgott R. Dissociation constants and relative efficacies <br>
of agonists acting on adrenergic alpha-receptors. Fed Proc 26: 410, 1967<br>
 <br>
NEPart = NESCALE*[NE] <br>
EpiPart = EPISCALE*[Epi]<br>
<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; EPISCALE - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
The EPISCALE is a constant which relates plasma levels of <br>
epinephrine to alpha agonism. Together with NESCALE, <br>
normal plasma levels of epinephrine and NE are mapped to <br>
an alpha agonism of 1.0.    <br>
 <br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; EpiPart - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Since alpha receptors see both epinephrine and <br>
norepinephrine, the blood concentration of epinephrine <br>
and norepinephrine do not quantitate either's effect on <br>
alpha receptors. In the model NE and Epi contribute equally <br>
to alpha agonism and normal plasma concentrations of NE and <br>
Epi are mapped to an alpha agonism of 1.0. <br>
This is done by using two constants NESCALE and EPISCALE to <br>
calculate NEPart & EpiPart respectively. <br>
 <br>
NEPart = NEScale*[NE] <br>
EpiPart = EPISCALE*[Epi]<br>
<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; MidoPart - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
MidoPart is used to calculate the effect of the alpha agonist<br>
midodrine on the alpha pool. It is a function of the amount of<br>
the active metabolite of midodrine, desglymidodrine and is <br>
calculated using the following formula:<br>
 <br>
MidoPart = DesglymidodrinePool.[Desglymidodrine]*MIDOSCALE<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; MIDOSCALE - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
The MIDOSCALE is a constant which relates plasma levels of <br>
the active metabolite of midodrine, desglymidodrine, to alpha <br>
agonism. <br>
 <br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Total - Definition1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Total alpha pool is the sum of the effects of epinephrine, <br>
norepinephrine and midodrine on alpha receptors. <br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
 <br>
End

<p><img src='../../Footer.PNG'>

</body>
</html>
